Pro Medicus Ltd (PME)
Australian Securities Exchange · Australia · prices in AUD · close of 22 Oct 2026
Key indicators
| Last close | AUD 193.42 |
|---|---|
| 52-week range | 107.75 – 289.20 |
| Return, 1 month / 3 months | +17.7% / +11.8% |
| Return, 1 year / 3 years | −31.7% / +150.0% |
| Trend | Uptrend |
| RSI (14) | 75 |
| Volatility (1 year) | 55.8% |
| Worst drawdown (1 year) | -61.7% |
| Average daily value traded | 38.12M AUD |
| Dividend yield | 0.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Pro Medicus Ltd is a healthcare software company based in Melbourne, Australia. It develops and licenses software for medical imaging, including radiology information systems and picture archiving and communication systems that hospitals and imaging clinics use to store, view and manage diagnostic images. Its Visage platform serves healthcare providers in Australia and overseas, particularly in the United States and Europe, where it is used by radiologists and clinicians in their daily work.
Pro Medicus Ltd trades under the code PME on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pro Medicus Ltd (PME) trades on the Australian Securities Exchange in Australia. It last closed at AUD 193.42 on 22 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 481 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 31.7% and over the last three months it rose 11.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 82 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 22.0% | ||
| From 52-week high | -32.0% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 11.8% | ||
| 6-month return | 37.9% | ||
| 12-month return, skipping the last month | -41.9% | ||
| Stability (higher is calmer) | 51 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 55.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -61.7% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 38.12M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | 26 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +18.2% |
|---|---|
| 1 month | +17.7% |
| 3 months | +11.8% |
| 6 months | +37.9% |
| 1 year | −31.7% |
| 3 years | +150.0% |
| 5 years | +261.4% |
Signals
| 50-day / 200-day average | 172.29 / 158.51 |
|---|---|
| Golden / death cross (60 days) | Golden, 53 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.78 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 7 Sep 2026 | AUD 0.3700 |
| 26 Feb 2026 | AUD 0.3200 |
| 3 Sep 2025 | AUD 0.3000 |
| 27 Feb 2025 | AUD 0.2500 |
| 4 Sep 2024 | AUD 0.2200 |
| 29 Feb 2024 | AUD 0.1800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.